Certain patients with chronic myeloid leukemia (CML) who take nilotinib daily may have achieved such deep remissions that they may be able to stop their treatment, according to a recent FDA decision
When the targeted oral therapy, imatinib (Gleevec®) was approved by the U.S. Food & Drug Administration (FDA) in 2001, it revolutionized treatment for patients with chronic myeloid leukemia (CML), turning an almost certain death sentence into a chronic disease for most patients who receive the diagnosis. LLS played a significant role in the drug’s discovery and development, funding the preclinical and clinical research of Brian Druker, M.D., whose work led to its approval.